Educational Level and First-time PSA Testing in General Practice
Overview
Authors
Affiliations
Different patterns in the use of prostate-specific antigen (PSA) testing might explain socioeconomic differences in prostate cancer incidence and mortality. We examined the association between socioeconomic position, measured as education and first-time PSA testing in general practice. A population-based cohort study of men aged 45-79 years without prior prostate cancer diagnosis living in the Capital Region of Denmark between 2000 and 2014. Information on socioeconomic indicators (education, income, cohabitation status and work market affiliation), prostate cancer diagnoses, and vital status were obtained from national registries. Date of first PSA test was obtained from the Copenhagen Primary Care Laboratory database. Temporal trends of PSA testing were calculated as annual age-standardised incidence rates and the association was examined by a multivariable Cox proportional hazards model. The cohort consists of 431,997 men of which 105,476 (24%) had a first-time PSA test in the study period. Men with longer education, higher income, living with a partner, and employed had higher rates of PSA testing. For men with short education, the rate of PSA test was 28.3 tests per 1000 person-years compared to 31.2 tests among men with long education. The fully adjusted hazard ratio for a first PSA test among men with short education was 0.87 (95% CI, 0.85-0.89) compared to men with long education. The association between education and first-time PSA testing indicates socioeconomic disparities in health care utilisation, which could explain part of the observed socioeconomic difference in prostate cancer incidence and mortality.
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
Bratt O, Auvinen A, Arnsrud Godtman R, Hellstrom M, Hugosson J, Lilja H BMJ Oncol. 2025; 2(1):e000039.
PMID: 39886507 PMC: 11203092. DOI: 10.1136/bmjonc-2023-000039.
Prostate Cancer Screening Uptake in Transgender Women.
Kalavacherla S, Riviere P, Kalavacherla S, Anger J, Murphy J, Rose B JAMA Netw Open. 2024; 7(2):e2356088.
PMID: 38353948 PMC: 10867675. DOI: 10.1001/jamanetworkopen.2023.56088.
Employment status among cancer survivors in a Late Effects Clinic in Denmark.
Skovgaards A, Mattsson T, Tolstrup L J Cancer Surviv. 2023; .
PMID: 38001283 DOI: 10.1007/s11764-023-01496-w.
Low-Value Prostate-Specific Antigen Screening in Older Males.
Kalavacherla S, Riviere P, Javier-Desloges J, Banegas M, McKay R, Murphy J JAMA Netw Open. 2023; 6(4):e237504.
PMID: 37040113 PMC: 10091155. DOI: 10.1001/jamanetworkopen.2023.7504.
Prescription rates for commonly used drugs before and after a prostate cancer diagnosis.
Larsen S, Dehlendorff C, Skriver C, Pottegard A, Friis S, Roder M Cancer Causes Control. 2022; 33(3):417-428.
PMID: 35006514 DOI: 10.1007/s10552-021-01537-8.